Lucida Medical is a healthcare technology company specializing in artificial intelligence (AI) software designed to improve the diagnosis and management of prostate cancer. Operating primarily within the medical imaging and diagnostics market, Lucida Medical collaborates with leading institutions such as the University of Cambridge and Hampshire Hospitals NHS Foundation Trust. The company's flagship product, Lucida Pi, leverages AI to analyze MRI images and clinical test data, offering a more accurate and less invasive method for diagnosing prostate cancer. This software is currently available through the Sectra Amplifier Marketplace, significantly expanding its reach within the healthcare sector. Lucida Medical's business model revolves around licensing its AI software to healthcare providers, generating revenue through subscription fees and usage-based pricing. The company serves radiologists, hospitals, and medical institutions, aiming to enhance precision medicine and improve patient outcomes. Pending FDA approval, Lucida Pi is not yet available for sale or clinical use in the USA.

Keywords: AI software, prostate cancer, MRI analysis, clinical diagnostics, healthcare technology, precision medicine, radiologists, medical imaging, Innovate UK, Sectra Amplifier Marketplace.